Psychotherapy and Psychosomatics

 

Neuropsychiatry and Pituitary Disease: An Overview

Weitzner M.A.

Author affiliations

H. Lee Moffitt Cancer Center,Tampa,Fla., USA

Keywords: PituitaryNeuropsychiatryPsychosomaticsBehavior

Related Articles for ""
Psychother Psychosom 1998;67:125–132
https://doi.org/10.1159/000012272

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: June 15, 1998
Issue release date: May – June

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0

ISSN: 0033-3190 (Print)
eISSN: 1423-0348 (Online)

For additional information: https://www.karger.com/PPS

Abstract

It has been recognized for some time that psychiatric symptoms, such as depression, anxiety, and behavioral alterations, may occur in patients who have pituitary disease. From other research focused on endocrine abnormalities seen in patients with psychiatric illness, it is understood that there is a significant interrelationship between the endocrine system and mental health. More recent research focusing on neural circuits in the brain and the impact of alterations in neurotransmission and neurohormonal modulation has shown that the prefrontal cortex can be affected by perturbations in functioning occurring in distant sites. Such is the situation with the hypothalamic-pituitary axis. Through its rich connections with other limbic structures, the hypothalamic-pituitary axis may affect the behavioral control exerted by the prefrontal cortex, causing mood and personality alterations. In the more severe cases, an apathy syndrome may develop which must be carefully differentiated from depression and other cognitive disorders. This report will review: (1) the neuroanatomical components that cause the behavioral changes observed in many patients with pituitary disease; (2) the current concept of apathy syndrome; (3) the differentiation of apathy syndrome from major depression; (4) the underlying neurobiology of apathy, and (5) potential treatments.



Related Articles:

References

  1. Addison T: On the constitutional and local effects of disease of the suprarenal capsules; in Wilkes S, Daldey E (eds): A Collection of the Unpublished Writings of Thomas Addison, vol. 36. London, New Sydenham Society, 1868.
  2. Cushing H: The basophil adenomas of the pituitary body and their clinical manifestations. Johns Hopkins Med J 1932;50:137–195.
  3. Sheehan HL: Simmonds disease due to post partum necrosis of the anterior pituitary. Q J Med 1939;8:277–307.
  4. Cushing H: Psychiatric disturbances associated with the ductless glands. Am J Insanity 1913;69:965–990.
  5. Starkman MN, Schteingart DE: Neuropsychiatric manifestations of patients with Cushing’s syndrome. Arch Intern Med 1981;141:215–219.
    External Resources
  6. Haskett RF: Diagnostic categorization of psychiatric disturbance in Cushing’s syndrome. Am J Psychiatry 1985;142:911–916.
    External Resources
  7. Holsboer FL: Psychoneuroendocrine strategies; in Fava GA, Wise TN (eds): Research Paradigms in Psychosomatic Research. Adv Psychosom Med. Basel, Karger, 1987, vol 17, pp 185–233.
  8. Holsboer F, Liebl R, Hofschuster E: Repeated dexamethasone suppression test during depressive illness. Normalization of test results compared with clinical improvement. J Affect Dis 1982;4:93–101.
    External Resources
  9. Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z: Dexamethasone suppression tests in antidepressant treatment of melancholia: The process of normalization and test‐retest reproducibility. Arch Gen Psychiatry 1983;40:493–500.
    External Resources
  10. Gerken A, Maier W, Holsboer F: Weekly monitoring of dexamethasone suppression response in depression. Its relationship to change of body weight and psychopathology. Psychoneuroendocrinology 1985;10:261–271.
    External Resources
  11. Greden JF, Albala AA, Haskett RF, James N, Goodman L, Steiner M, Carroll BJ: Normalization of dexamethasone suppression test. A laboratory index of recovery from endogenous depression. Biol Psychiatry 1980;15:449–458.
    External Resources
  12. Holsboer F, Steiger A, Maier W: Four cases of reversion to abnormal dexamethasone suppression test response as indicator of clinical relapse. A preliminary report. Biol Psychiatry 1983;18:911–916.
    External Resources
  13. Herman JP, Schafter MK, Young EA, Thompson R, Douglass J, Akil H, Watson SJ: Evidence for hippocampal regulation of neuroendocrine neurons of the hypothalamic‐pituitary‐adrenocortical axis. J Neurosci 1989;9:3072–3082.
    External Resources
  14. McEwen BS, De Kloet ER, Rostene WH: Adrenal steroid receptors in the nervous system. Physiol Rev 1986;66:1121–1150.
    External Resources
  15. Kornstein SG, Gardner DF: Endocrine disorders; in Stoudemire A, Fogel BS (eds): Psychiatric Care of the Medical Patient. New York, Oxford University Press, 1993, pp 657–679.
  16. Fava GA, Sonino N, Morphy MA: Psychosomatic view of endocrine disorders. Psychother Psychosom 1993;59:20–33.
    External Resources
  17. Loosen PT: Cushing’s syndrome and depression. Endocrinologist 1994;4:373–382.
  18. Marin RS: Differential diagnosis and classification of apathy. Am J Psychiatry 1990;147:22–30.
    External Resources
  19. Van Hoesen GW, Morecraft RJ, Semendeferi K: Functional neuroanatomy of the limbic system and prefrontal cortex; in Fogel BS, Schiffer RB, Rao SM (eds): Neuropsychiatry. Baltimore, Williams & Wilkins, 1996, pp 113–143.
  20. Devinsky O: Behavioral Neurology: 100 Maxims. St. Louis, Mosby Year Book, 1992.
  21. Mueller J, Fogel BS: Neuropsychiatric examination; in Fogel BS, Schiffer RB, Rao SM (eds): Neuropsychiatry. Baltimore, Williams & Wilkins, 1996, pp 11–28.
  22. Fuster JM: Frontal lobe syndromes; in Fogel BS, Schiffer RB, Rao SM (eds): Neuropsychiatry. Baltimore, Williams & Wilkins, 1996, pp 407–413.
  23. MacLean P: Some psychiatric implications of physiological studies on frontotemporal portion of limbic system (visceral brain). Electroencephalogr Clin Neurophysiol 1952;4:407–418.
    External Resources
  24. Papez JW: A proposed mechanism of emotion. Arch Neurol Psychiatry 1937;38:725–743.
  25. Damasio AR, Van Hoesen GW: Emotional disturbances associated with focal lesions of the limbic frontal lobe; in Heilman KM, Satz P (eds): Neuropsychology of Human Emotion. New York, Guilford Press, 1983, pp 85–108.
  26. Nieuwenhuys R, Voogd J, Van Huijzen C: The Human Central Nervous System: A Synopsis and Atlas, ed 3. New York, Springer, 1988, pp 293–363.
  27. Folkard S: Time of day and level of processing. Mem Cogn 1979;7:247–252.
  28. Hockey GRJ, Colquhoun WP: Diurnal variation in human performance: A review; in Colquhoun WP (ed): Aspects of Human Efficiency: Diurnal Rhythm and Loss of Sleep. London, English Universities Press, 1972.
  29. DeMoranville BM, Jackson IMD: Psychoneuroendocrinology; in Fogel BS, Schiffer RB, Rao SM (eds): Neuropsychiatry. Baltimore, Williams & Wilkins, 1996, pp 173–192.
  30. Marin RS: Apathy: A neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991;3:243–254.
    External Resources
  31. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143–162.
    External Resources
  32. Geschwind N: The borderlands of neurology and psychiatry: Some common misconceptions; in Benson DF, Blumer D (eds): Psychiatric Aspects of Neurologic Disease. New York, Grune & Stratton, 1975, pp 1–9.
  33. Marin RS: Apathy and related disorders of diminished motivation; in Dickstein LJ, Riba MB, Oldham JM (eds): Review of Psychiatry, vol 15. Washington, American Psychiatric Press, 1996, pp 205–242.
  34. Albin RL, Young AB, Penney JB: The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366–375.
    External Resources
  35. Alexander GE, Crutcher MD: Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci 1990;13:266–271.
    External Resources
  36. Groenewegen HJ, Roeling TAP, Voorn P: The parallel arrangement of basal ganglia‐thalamocortical circuits: A neuronal substrate for the role of dopamine in motor and cognitive functions?; in Wolters EC, Scheltens P (eds): Mental Dysfunction in Parkinson’s Disease. Amsterdam, Vrije Universiteit, 1993, pp 3–18.
  37. Stuss DT, Benson DF: The Frontal Lobes. New York, Raven Press, 1975.
  38. Marin RS: Apathy: Concept, syndrome, neural mechanisms, and treatment. Sem Neuropsychiatry 1996;1:304–314.
  39. Marin RS: Apathy – Who cares? An introduction to apathy and related disorders of diminished motivation. Psychiatr Ann 1997;27:18–23.
  40. Campbell JJ, Duffy JD: Treatment strategies in amotivated patients. Psychiatr Ann 1997;27:44–49.
  41. Alexander GE: Basal ganglia‐thalamocortical circuits: Their role in control of movements. J Clin Neurophysiol 1994;11:420–431.
    External Resources
  42. Kalivas PW, Barnes CD: Limbic Motor Circuits and Neuropsychiatry. Boca Raton, CRC Press, 1993.
  43. Willner P, Scheel‐Kruger J: The mesolimbic dopamine system; in Willner P, Scheel‐Kruger J (eds.): Motivation to Action. New York, Wiley, 1991.
  44. Beck AT, Weishaar M: Cognitive therapy; in Freeman A, Simon K, Beutler L, Arkowitz H (eds): Comprehensive Handbook of Cognitive Therapy. New York, Plenum, 1989, pp 21–36.
  45. Cummings JL: Frontal‐subcortical circuits and human behavior. Arch Neurol 1993;50:873–880.
    External Resources
  46. Mega MS, Cummings JL: Frontal‐subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994;6:358–370.
    External Resources
  47. Hecaen H, Albert M: Disorders of mental functioning related to frontal lobe pathology; in Benson DF, Blumer D (eds): Psychiatric Aspects of Neurologic Disease. New York, Grune & Stratton, 1975, pp 137–149.
  48. Gentilini M, De Renzi E, Crisi G: Bilateral paramedian thalamic artery infarcts: Report of eight cases. J Neurol Neurosurg Psychiatry 1987;50:900–909.
    External Resources
  49. Eslinger PJ, Warner GC, Grattan LM, Easton JD: ‘Frontal lobe’ utilization behavior associated with paramedian thalamic infarction. Neurology 1991;41:450–452.
    External Resources
  50. Stuss DT, Guberman A, Nelson R, Larochelle S: The neuropsychology of paramedian thalamic infarction. Brain Cogn 1988;8:348–378.
    External Resources
  51. Marin RS, Firinciogullari MS, Biedrzycki RC: Group differences in the relationship between apathy and depression. J Nerv Ment Dis 1994;182:235–239.
    External Resources
  52. Morgenson GJ, Brudzynski SM, Wu M, Yang CR, Yim CCY: From motivation to action: A review of dopaminergic regulation of limbic – nucleus accumbens – ventral pallidum – pedunculopontine nucleus circuitries involved in limbic‐motor integration; in Kalivas PW, Barnes CD (eds): Limbic Motor Circuits and Neuropsychiatry. Boca Raton, CRC Press, 1993, pp 193–236.
  53. Sablowski N, Pawlik K, Ludecke DK, Herrmann H‐D: Aspects of personality inpatients with pituitary adenomas. Acta Neurochir (Wien) 1986;83:8–11.
    External Resources
  54. Cohen LM, Greenberg DB, Murray GB: Neuropsychiatric presentation of men with pituitary tumors (the ‘four A’s’). Psychosomatics 1984;25:925–928.
    External Resources
  55. Price TRP, Goetz KL, Lovell MR: Neuropsychiatric aspects of brain tumors; in Yudofsky SC, Hales RE (eds): Textbook of Neuropsychiatry. Washington, American Psychiatric Press, 1997, pp 635–662.
  56. Grattan‐Smith PJ, Morris JGL, Shores EA, Batchelor J, Sparks RS: Neuropsychological abnormalities in patients with pituitary tumors. Acta Neurol Scand 1992;86:626–631.
    External Resources
  57. Corrigan PW: Models of ‘normal’ cognitive functioning; in Corrigan PW, Yudofsky SC (eds): Cognitive Rehabilitation for Neuropsychiatric Disorders. Washington, American Psychiatric Press, 1996, pp 3–51.
  58. Corrigan PW, Yudofsky SC: What is cognitive rehabilitation?; in Corrigan PW, Yudofsky SC (eds): Cognitive Rehabilitation for Neuropsychiatric Disorders. Washington, American Psychiatric Press, 1996, pp 53–69.
  59. Hoehn‐Saric R, Lipsey JR, McLeod DR: Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 1990;32:672–674.
  60. Duffy JD, Marin RS: Recent advances in the neuropsychiatry of disorders of motivation. J Neuropsychiatry Clin Neurosci 1995;7:397.
  61. Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B: Apathy: A treatable syndrome. J Neuropsychiatry Clin Neurosci 1995;7:23–30.
    External Resources
  62. Kaplitz S: Withdrawn, apathetic geriatric patients responsive to methylphenidate. J Am >chGeriatr Soc 1975;123:271–276.
  63. Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer’s disease: An open‐label study. J Geriatr Psychiatry Neurol 1996;9:1–6.
    External Resources
  64. Weitzner MA, Meyers CA, Valentine AD: Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995;7:347–350.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: June 15, 1998
Issue release date: May – June

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0

ISSN: 0033-3190 (Print)
eISSN: 1423-0348 (Online)

For additional information: https://www.karger.com/PPS

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

1998, Vol.67, No. 3

May – June

Article

Recommend This
TOP